Surface Oncology, Inc. (SURF)

Urges Stockholders to Vote Promptly to Ensure Their Shares are Represented at the September 7th Special Meeting Urges Stockholders to Vote Promptly to Ensure Their Shares are Represented at the September 7th Special Meeting

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Surface Oncology, Inc. (NasdaqGM: SURF) to Coherus BioSciences, Inc. (NasdaqGM: CHRS). Under the terms of the proposed transaction, Coherus will issue shares of its common stock at a price of $5.2831 per share to acquire all outstanding shares of Surface stock. Surface shareholders will also receive certain Co.

CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the second quarter 2023.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Surface Oncology, Inc. (NasdaqGM: SURF) to Coherus BioSciences, Inc. (NasdaqGM: CHRS). Under the terms of the proposed transaction, Coherus will issue shares of its common stock at a price of $5.2831 per share to acquire all outstanding shares of Surface stock. Surface shareholders will also receive certain Co.

This will likely be another active week for traders. Whether you're trading penny stocks or higher priced shares of companies like Tesla (NASDAQ: TSLA) and Apple (NASDAQ: AAPL), chances are you're paying attention to stock market news headlines.

Surface Oncology shares jumped by more than 16% on Friday morning after it was revealed the clinical-stage immuno-oncology (I-O) company is being acquired by Coherus BioSciences (NASDAQ:CHRS). The stock-for-stock transaction is valued at up to $65 million, approximately a three-fold premium over Surface's anticipated net cash of $20 million to $25 million at closing, the two companies said in a statement.

Surface Oncology Inc. SURF, +1.37% stock is up 49% in premarket trades on Friday after the cancer drug company agreed to be acquired by Coherus BioSciences Inc. CHRS, +0.56% in a stock-for-stock deal valued at up to $65 million. Coherus will issue shares of its common stock at a price of $5.2831 per share to acquire all outstanding shares of Surface stock for a total value equal to the sum of $40 million.

NEW YORK, May 11, 2023 The subsea umbilicals, risers, and flow lines (SURF) market size is estimated to increase by USD 5.2 billion from 2022 to 2027. The market is expected to grow at a CAGR of 10.7%, according to the recent market study by Technavio. This report also offers a 5-year historical (2017-2021) data projection […]...

Data further support SRF388 and SRF114 clinical development programs Data further support SRF388 and SRF114 clinical development programs

- New preclinical data indicate IL-27 induces a gene expression signature  that has been associated with resistance to chemotherapy, radiotherapy, and checkpoint inhibition -

CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a fireside chat at the Baird 2022 Global Healthcare Conference on Wednesday, September 14, 2022, at 10:15 a.m. ET.

– SRF388 demonstrated clinical activity in multiple solid tumor types with three confirmed partial responses across NSCLC, RCC and HCC –

Surface Oncology has been a major drag for investors. There's no bad news, but there's no good news either.

CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in two upcoming investor conferences:

CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it will share a clinical update on SRF388 in an oral presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting, to be held June 3-7, 2022 in Chicago, Il.

What you need to know about trading penny stocks on March 11th The post Trading Penny Stocks? Top Stock Market News for March 11th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.